Doxorubicin Hydrochloride [HCl]

Phase 2

Doxorubicin Hydrochloride [HCl] is one of 28 therapeutic programs targeting Non-Hodgkin Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Non-Hodgkin LymphomaActive, not recruiting

Non-Hodgkin LymphomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

34 competitors in Non-Hodgkin Lymphoma

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

5 2

Actemra

Roche

Phase 3

3 3

LUNSUMIO

Roche

Phase 3

2 4

Polivy

Roche

Phase 3

2 5

Epkinly

Genmab

Phase 2

3 6

Adriamycin

Pfizer

Phase 2

1 7

Cytoxan

BBaxter Healthcare Corporation

Phase 2

6 8

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

3 9

Imbruvica

PPharmacyclics LLC.

Phase 2

2 10

Rayos

RRoxane Laboratories

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2032

Phase 2Active, not recruiting

Non-Hodgkin Lymphoma

NCT05283720

Clinical

Trials by Indication[1]

Non-Hodgkin Lymphoma1 trial

Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin Lymphoma

Active, not recruiting· Genmab logo

Genmab·Phase 2·NCT05283720·264 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Doxorubicin Hydrochloride [HCl]. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Doxorubicin Hydrochloride [HCl]. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Genmab company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: Genmab

Doxorubicin Hydrochloride [HCl]

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2032

Trials by Indication[1]

Non-Hodgkin Lymphoma1 trial

References

Drug Info

Quick Facts

Related News